On March 6, 2025, the Connecticut State Legislature introduced Senate Bill 11, a significant legislative proposal aimed at establishing a Canadian prescription drug importation program. This bill seeks to address the rising costs of prescription medications by allowing the state to import drugs from Canada, contingent upon federal approval.

The primary purpose of Senate Bill 11 is to create a framework for the importation of prescription drugs that meet both federal and state safety standards. Key provisions of the bill include a requirement for the Commissioner of Consumer Protection to assess the feasibility of the program and submit a request to the federal Food and Drug Administration (FDA) for approval under specific sections of the federal Food, Drug, and Cosmetic Act. The request must outline the operational plans for the program, demonstrate compliance with safety and effectiveness standards, and provide an estimate of implementation costs.

Debate surrounding the bill has highlighted concerns regarding the safety and efficacy of imported drugs, as well as the potential economic implications for local pharmacies and healthcare providers. Proponents argue that the bill could significantly reduce prescription drug costs for consumers, while opponents caution against potential risks associated with drug importation, including the possibility of counterfeit medications entering the market.

If approved by the FDA, the Commissioner of Consumer Protection would be required to notify various state agencies and legislative committees about the approval, ensuring transparency and oversight. The bill's passage could have far-reaching implications for healthcare affordability in Connecticut, potentially setting a precedent for other states considering similar measures.

As discussions continue, experts emphasize the importance of balancing cost savings with patient safety, suggesting that careful monitoring and regulation will be crucial if the program moves forward. The outcome of Senate Bill 11 could reshape the landscape of prescription drug pricing in Connecticut and beyond, making it a pivotal point of interest for lawmakers and constituents alike.